{"blog": [], "keywords": [{"value": "Pfizer Inc", "name": "organizations", "rank": "1", "is_major": "N"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Anacor Pharmaceuticals Inc", "name": "organizations", "rank": "4", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/05/17/business/dealbook/pfizer-to-acquire-anacor-pharmaceuticals-for-5-2-billion.html", "document_type": "article", "byline": {"person": [{"lastname": "PICKER", "firstname": "Leslie", "role": "reported", "organization": "", "rank": 1}], "original": "By LESLIE PICKER"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/05/17/business/db-pfizer1/db-pfizer1-thumbWide.jpg", "legacy": {"wide": "images/2016/05/17/business/db-pfizer1/db-pfizer1-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/05/17/business/db-pfizer1/db-pfizer1-articleLarge.jpg", "legacy": {"xlarge": "images/2016/05/17/business/db-pfizer1/db-pfizer1-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/05/17/business/db-pfizer1/db-pfizer1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/05/17/business/db-pfizer1/db-pfizer1-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "303", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "After terminating deals with AstraZeneca and most recently, Allergan, Pfizer has turned to relatively smaller biotech companies for acquisitions.", "pub_date": "2016-05-17T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Pfizer Refocuses, Scooping Up a Smaller Biotech Company", "main": "Pfizer to Acquire Anacor Pharmaceuticals for $5.2 Billion"}, "print_page": "3", "snippet": "After terminating deals with AstraZeneca and most recently, Allergan, Pfizer has turned to relatively smaller biotech companies for acquisitions.", "_id": "5739bae338f0d83bc1f16496", "slideshow_credits": null, "abstract": null}